TraderHan
2021-12-30
Ok
Biogen Dropped 5% in Premarket Trading<blockquote>Biogen在盘前交易中下跌5%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":692344538,"tweetId":"692344538","gmtCreate":1640861220836,"gmtModify":1640861220910,"author":{"id":3564048100321619,"idStr":"3564048100321619","authorId":3564048100321619,"authorIdStr":"3564048100321619","name":"TraderHan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/692344538","repostId":1198596106,"repostType":4,"repost":{"id":"1198596106","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640855595,"share":"https://www.laohu8.com/m/news/1198596106?lang=zh_CN&edition=full","pubTime":"2021-12-30 17:13","market":"us","language":"en","title":"Biogen Dropped 5% in Premarket Trading<blockquote>Biogen在盘前交易中下跌5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198596106","media":"Tiger Newspress","summary":"U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying","content":"<p><html><head></head><body>U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying Samsung in talks to acquire Biogen.<img src=\"https://static.tigerbbs.com/0d21708fdbb17a292f7748f78750b030\" tg-width=\"1121\" tg-height=\"718\" referrerpolicy=\"no-referrer\"/>Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.</p><p><blockquote><html><head></head><body>美国制药商百健(Biogen Inc)在盘前交易中下跌5%，三星生物制品公司否认了有关三星正在洽谈收购百健(Biogen)的报道。三星生物制品公司周四否认了媒体报道，该报道称这家韩国公司正在就收购美国制药商百健公司进行谈判。</body></html></blockquote></p><p>Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.</p><p><blockquote>《韩国经济日报》周三援引投行消息人士的话报道称，百健（Biogen）已与三星接洽，希望购买其股票，估值可能超过420亿美元。根据Refinitiv的数据，Biogen的估值为346.7亿美元。</blockquote></p><p>Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was "not true," without giving any more details.</p><p><blockquote>三星集团的生物技术部门三星生物制品公司在一份监管文件中表示，该报道“不属实”，但没有提供更多细节。</blockquote></p><p>Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.</p><p><blockquote>Biogen表示，不对市场传言或猜测发表评论。其股价周三收盘上涨9.5%。</blockquote></p><p>Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.</p><p><blockquote>任何此类交易都将是韩国公司有史以来最大的海外收购。迄今为止最大的一次是在2016年，当时三星电子以80亿美元的价格收购了汽车电子制造商哈曼国际工业公司。</blockquote></p><p>Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.</p><p><blockquote>三星集团今年早些时候曾表示，将在未来三年内投资240万亿韩元（2060亿美元），以在后疫情时代扩大其在生物制药、人工智能、半导体和机器人领域的足迹。</blockquote></p><p>In June, Biogen's controversial Alzheimer's drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel's view that the company had not proven the treatment's clinical benefits.</p><p><blockquote>今年6月，百健(Biogen)备受争议的阿尔茨海默病药物获得了美国监管机构的批准，成为近20年来首个治疗这种记忆丧失疾病的新疗法，尽管外部顾问小组认为该公司尚未证明该疗法的临床益处。</blockquote></p><p>Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.</p><p><blockquote>百健(Biogen)一直押注于药物Aduhelm，以缓冲其主要收入驱动因素（如多发性硬化症治疗药物Tecfidera和肌肉疾病治疗药物Spinraza）面临日益激烈的竞争。</blockquote></p><p>But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug's high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.</p><p><blockquote>但Aduhelm在美国的销售慢于预期，因为医院抱怨该药物的高成本与其收益不相称。该公司本月将价格下调了约一半至28,200美元。</blockquote></p><p>Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.</p><p><blockquote>Biogen是一家生产神经系统疾病药物的公司，目前其产品线中有30多种新药。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Dropped 5% in Premarket Trading<blockquote>Biogen在盘前交易中下跌5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Dropped 5% in Premarket Trading<blockquote>Biogen在盘前交易中下跌5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-30 17:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying Samsung in talks to acquire Biogen.<img src=\"https://static.tigerbbs.com/0d21708fdbb17a292f7748f78750b030\" tg-width=\"1121\" tg-height=\"718\" referrerpolicy=\"no-referrer\"/>Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.</p><p><blockquote><html><head></head><body>美国制药商百健(Biogen Inc)在盘前交易中下跌5%，三星生物制品公司否认了有关三星正在洽谈收购百健(Biogen)的报道。三星生物制品公司周四否认了媒体报道，该报道称这家韩国公司正在就收购美国制药商百健公司进行谈判。</body></html></blockquote></p><p>Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.</p><p><blockquote>《韩国经济日报》周三援引投行消息人士的话报道称，百健（Biogen）已与三星接洽，希望购买其股票，估值可能超过420亿美元。根据Refinitiv的数据，Biogen的估值为346.7亿美元。</blockquote></p><p>Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was "not true," without giving any more details.</p><p><blockquote>三星集团的生物技术部门三星生物制品公司在一份监管文件中表示，该报道“不属实”，但没有提供更多细节。</blockquote></p><p>Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.</p><p><blockquote>Biogen表示，不对市场传言或猜测发表评论。其股价周三收盘上涨9.5%。</blockquote></p><p>Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.</p><p><blockquote>任何此类交易都将是韩国公司有史以来最大的海外收购。迄今为止最大的一次是在2016年，当时三星电子以80亿美元的价格收购了汽车电子制造商哈曼国际工业公司。</blockquote></p><p>Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.</p><p><blockquote>三星集团今年早些时候曾表示，将在未来三年内投资240万亿韩元（2060亿美元），以在后疫情时代扩大其在生物制药、人工智能、半导体和机器人领域的足迹。</blockquote></p><p>In June, Biogen's controversial Alzheimer's drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel's view that the company had not proven the treatment's clinical benefits.</p><p><blockquote>今年6月，百健(Biogen)备受争议的阿尔茨海默病药物获得了美国监管机构的批准，成为近20年来首个治疗这种记忆丧失疾病的新疗法，尽管外部顾问小组认为该公司尚未证明该疗法的临床益处。</blockquote></p><p>Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.</p><p><blockquote>百健(Biogen)一直押注于药物Aduhelm，以缓冲其主要收入驱动因素（如多发性硬化症治疗药物Tecfidera和肌肉疾病治疗药物Spinraza）面临日益激烈的竞争。</blockquote></p><p>But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug's high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.</p><p><blockquote>但Aduhelm在美国的销售慢于预期，因为医院抱怨该药物的高成本与其收益不相称。该公司本月将价格下调了约一半至28,200美元。</blockquote></p><p>Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.</p><p><blockquote>Biogen是一家生产神经系统疾病药物的公司，目前其产品线中有30多种新药。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198596106","content_text":"U.S. drugmaker Biogen Inc dropped 5% in premarket trading, as Samsung Biologics denied report saying Samsung in talks to acquire Biogen.Samsung BioLogics on Thursday denied a media report that said the South Korean firm was in talks to buy U.S. drugmaker Biogen Inc.Korea Economic Daily reported on Wednesday, citing investment banking sources, that Biogen had approached Samsung to buy its shares, which could be valued at more than $42 billion. Biogen is valued at $34.67 billion, according to Refinitiv data.Samsung BioLogics, the biotech unit of Samsung Group, said in a regulatory filing that the report was \"not true,\" without giving any more details.Biogen said it does not comment on market rumors or speculation. Its stock closed up 9.5% on Wednesday.Any such deal would be the biggest overseas acquisition ever by a South Korean company. The largest so far was in 2016, when Samsung Electronics bought auto electronics maker Harman International Industries in an $8 billion deal.Samsung Group had said earlier this year it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.In June, Biogen's controversial Alzheimer's drug won U.S. regulatory approval, becoming the first new treatment for the memory-robbing disease in nearly 20 years, despite an outside advisory panel's view that the company had not proven the treatment's clinical benefits.Biogen has been betting on the drug, Aduhelm, to buffer a hit as its main revenue drivers such as multiple sclerosis treatment Tecfidera and muscle disease treatment Spinraza face rising competition.But U.S. sales from Aduhelm have been slower than expected as hospitals complained that the drug's high cost was not worth its benefits. The company cut its price by about half to $28,200 this month.Biogen, which makes drugs for neurological diseases, currently has more than 30 new drugs in its pipeline.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":2836,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/692344538"}
精彩评论